Dermal Cell News is an online publication and email newsletter highlighting the latest research about wound healing, skin disorders, and dermal cancers.
As the largest organ in the human body, the skin is implicated in a wide range of health conditions. Dermal Cell News is dedicated to covering it all. Our website, newsletter, and Twitter feed highlight research on tissue regeneration in the treatment of skin wounds, burns, cancers, and disorders. We also feature relevant job postings and upcoming events.
Investigators developed a mouse glabrous skin behavioral assay to investigate the contribution of three previously identified pruriceptive neurons in glabrous skin itch.
[Proceedings of the National Academy of Sciences of the United States of America]
AbbVie announced that the US FDA has extended the review period for the supplemental New Drug Application for upadacitinib in the treatment of adults and adolescents with moderate to severe atopic dermatitis.
Scientists showed that promoter hypermethylation of cGAS and stimulator of interferon genes (STING) mediated their coordinated transcriptional silencing and contributed to the widespread impairment of the STING signaling function in clinically-relevant human melanomas and melanoma cell lines.
[Proceedings of the National Academy of Sciences of the United States of America]
Investigators revealed a role for myeloid-derived cells-derived hypochlorous acid (HOCl) as a small-molecule paracrine signaling factor that trans-inhibited inhibited IκB kinase (IKK) in melanoma tumor cells, mediating antitumor responses during early tumor progression.
Scientists showed that PMEPA1 promoted tumorigenic traits and that CSDE1 along with miR-129-5p/AGO2 miRISC acted antagonistically to fine-tune PMEPA1 expression toward the progression of melanoma.
Some new medications may improve patient outcomes, others may not offer meaningful benefits vs existing less costly alternatives, especially in dermatology, in which subtle changes in the concentration or combination of topical agents can be classified as a novel product.
Pfizer, Inc. announced that the US FDA has extended the priority review period for the New Drug Application for abrocitinib for the treatment of adults and adolescents with moderate to severe atopic dermatitis.
The authors studied the functional role of complement factor I (CFI) in the progression of cutaneous squamous cell carcinoma (cSCC). CFI was knocked down in cSCC cells and RNA‐seq analysis was performed.
